{"id":"NCT01511809","sponsor":"IRCCS San Raffaele","briefTitle":"Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression","officialTitle":"Efficacy of Atazanavir / Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression. Randomized, Open Label Non Inferiority Trial. A Phase 3 Study.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2013-07","completion":"2015-05","firstPosted":"2012-01-19","resultsPosted":"2014-11-24","lastUpdate":"2024-02-09"},"enrollment":117,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"Atazanavir/ritonavir monotherapy","otherNames":["ATV/r monotherapy"]}],"arms":[{"label":"Atazanavir/ritonavir monotherapy","type":"EXPERIMENTAL"},{"label":"Atazanavir/ritonavir triple therapy","type":"NO_INTERVENTION"}],"summary":"The study will assess whether Atazanavir/ritonavir monotherapy provides a non-inferior proportion of virological efficacy with respect to ATV/RTV + 2 NRTIs in patients with stable suppressed viremia and no prior virologic failures.","primaryOutcome":{"measure":"Proportion of Patients With Treatment Failure (TF)","timeFrame":"Up to week 48","effectByArm":[{"arm":"Atazanavir/Ritonavir Monotherapy","deltaMin":27.5,"sd":null},{"arm":"Atazanavir/Ritonavir Triple Therapy","deltaMin":15.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":6},"locations":{"siteCount":1,"countries":["Italy"]},"refs":{"pmids":["18195565","18540803","18097218","19349870","20010070","20802297","16905786","17159658","19191590","17545707"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":51},"commonTop":["acute hepatitis","nephrolitiasis","gross haematuria with proteinuria","cholecystitis due to cholelithiasis","hyperuricemia"]}}